ABSTRACT
INTRODUCTION
Recent randomized controlled trials show that reduction in intraocular pressure (IOP) results in reduction in the rate of visual loss in most glaucoma patients [1] . In many studies the assumption is made that IOP control implies a single, or occasionally, a few daytime IOP measurements over time. Although the follow-up of glaucoma patients with single IOP measurements is quick and convenient, such measurements often do not reflect IOP control during the 24-h cycle [2] [3] [4] . Since glaucoma is a 24-h disease and the damaging effect of elevated IOP is continuous [5] , it is logical that we should aim to control the IOP throughout the 24-h period. This article reviews the value and future promise of 24-h IOP monitoring and discusses recent 24-h efficacy evidence on available glaucoma treatment options. The review is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
A single IOP measurement gives data for only 1 min of the day and may not reflect the dynamic equilibrium during the other 1439 min of that day, or the IOP level between appointments.
Even three or four measurements may not reflect glaucoma status. Current routine clinical practice involves single IOP readings at each patient visit owing to time/cost considerations.
Consequently, the quality of IOP data, which we rely upon to diagnose and treat glaucoma and to choose between therapeutic options (medical, laser, surgery) is often inadequate and can be misleading [2, [5] [6] [7] [8] [9] [10] [11] . Ideally, a 24-h time-IOP profile, both without and following treatment, will optimize management and help determine the future probability and rate of deterioration in vision. Such data will also enhance our understanding of the role of elevated IOP in glaucoma initiation and progression.
The concept of 24-h IOP assessment and control has aroused interest in recent literature and its application may hold future promise. Twenty-four-hour blood pressure monitoring is widely employed to assist patient management.
Similarly, 24-h IOP monitoring can enhance the quality of IOP data and guide glaucoma management. Firstly, evaluation of untreated 24-h IOP, prior to initiation of therapy, provides the true peak IOP and the 24-h IOP profile. Secondly, 24-h IOP monitoring elicits the IOP level at which damage probably occurred and allows an optimal target IOP to be set. Finally, the relationship between damage and IOP is elicited in the individual patient [3-5, 8, 9] .
The key 24-h characteristics are: (a) the mean 24-h IOP, (b) the fluctuation of 24-h IOP, and (c) the peak 24-h IOP. As yet the value of 24-h IOP testing in the long-term prognosis of glaucoma remains unproven. However, those with the worst untreated 24-h characteristics tend to show greater deterioration. This was demonstrated in a 24-h IOP study [7] , which found a strong linear correlation between untreated peak IOP in exfoliation glaucoma (XFG; r = 0. 71 ) and primary open-angle glaucoma (POAG; r = 0.44) and perimetric mean deviation at the time of diagnosis. A similar strong association was detected between mean 24-h IOP and untreated mean visual field loss in both XFG (r = 0.77) and POAG (r = 0.28) [7] . Hence, it is logical to assume that the worse 24-h IOP characteristics in XFG may account for the faster deterioration and worse prognosis.
For each patient with glaucoma, diurnal or 24-h IOP data will enhance our understanding of the role of elevated IOP in glaucoma initiation and progression. Although in this context it would appear ideal to obtain information on the 24-h control of all our glaucoma patients this is not a realistic strategy for most patients in most health systems. In contrast, reliable guidance on the 24-h efficacy of all available treatment options can be obtained by carrying out well-designed, randomized controlled trials, which, when published, can influence everyday practice. For example, a complete 24-h assessment of all monotherapy options will allow better separation between them and guide our day-to-day clinical management. Then, controlled 24-h IOP studies can supply convincing evidence for the superiority of a specific combined therapy regimen thus optimizing stepwise therapy. This is supported by previously published evidence comparing various medical therapy regimens where the true efficacy profile would not have been detected if it had not been for a complete 24-h IOP study. As evidenced by such studies, 24-h efficacy can differ meaningfully from daytime efficacy [10, [12] [13] [14] 21] . In the future, this research can also remove ambiguity as to the true efficacy of laser therapy and the overall success of a number of novel surgical options versus the gold standard surgical selection of trabeculectomy with mitomycin C. Over the last decade 24-h IOP monitoring has allowed us to investigate the 24-h efficacy of many new antiglaucoma drugs [7, 10, 12, 13, 15, 18, 19, 21, 23] (27.8-28 .6%) which compares well with the previously reported short-term 24-h efficacy of travoprost monotherapy [6] . There is some evidence to suggest that surgery provides better 24-h characteristics and yields a narrower 24-h fluctuation of IOP compared with laser and medical therapy [29, 30] . On the other hand, recent 24-h studies have indicated that a number of new antiglaucoma drugs (prostaglandin analogs, fixed combinations) significantly reduce 24-h fluctuation of IOP [6, 12, 15, 18, 23] . It is not known how adjunctive therapy with these drugs compares to successful laser, or surgery.
Further research is needed on the quality of 24-h IOP control obtained with the various therapeutic options. Little is currently known on the relationship between 24-h IOP characteristics with available treatment choices and the stage of glaucoma. Despite the fact that 24-h IOP characteristics probably vary in different types of glaucoma, our knowledge concerning how this relates to the choice of therapy is almost non-existent.
IOP fluctuates normally throughout the day by around 4-6 mmHg [2, 3, 5] . In ocular hypertensives, the diurnal fluctuation averages 6-8 mmHg, with a high of 15 mmHg possible [1, 2, 4] . In patients with glaucoma, the 24-h variation in IOP ranges between 6 and 15 mmHg with an upper limit of about 40 mmHg in extreme cases [2] [3] [4] . Typically, in most 24-h studies [2, 7, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] on patients with glaucoma the untreated IOP is highest in the morning (between 6:00 am and 12:00 pm). In most of our patients the 10:00 am IOP measurement yields the highest mean IOP values [7, [12] [13] [14] [15] [16] [17] [18] [19] . This accords with the aqueous synthesis pattern, which is significantly reduced during sleep at night [31] . However, there are many exceptions to this rule and the peak pressure may occur at any time throughout the day. The type of glaucoma can also influence the timing of peak IOP. In one study [3] , 45% of patients with XFG and 22.5% of those with POAG exhibited the peak level of IOP outside office hours.
The timing and number of measurements can obviously influence the results: more measurements lead to more accurate 24- 
PATTERNS OF 24-H IOP IN HEALTH AND DISEASE

Pattern of IOP in Healthy Eyes
Tonometry performed over a 24-h period may be subdivided into diurnal (daytime) and nocturnal (nighttime) pressure measurements.
In most patients the rhythmic pattern of IOP oscillation exhibits peaks in the morning and troughs in the evening. In healthy normotensive eyes, the 24-h IOP fluctuation typically lies within a 5 mmHg range [2, [32] [33] [34] [35] [36] .
Drance [32] One important parameter that can influence IOP fluctuation is body posture; the IOP measured in the sitting position is generally lower than that measured in the supine position at any given time [22, [37] [38] [39] [40] . In a diurnal study performed by Chiquet and coworkers [37] , supine IOP was significantly higher than sitting IOP, with a mean pressure difference of 2.2 ± 2.9 mmHg after 1 min, 0.9 ± 3 mmHg after 3 min, and 1.9 ± 3.8 mmHg after 10 min (P\0.001). Nevertheless, during a seven-day head-down tilt bed rest, eyes seemed to compensate for the IOP elevation after patients assumed the head-down position and eventually exhibited a slight and progressive decrease of IOP (1.3 mmHg) compared to the baseline supine IOP [37] . The decrease in IOP reached a peak value at the end of the week of the head-down position. In a 24-h study conducted by Liu et al. [38] , 33 volunteers were housed in a sleep laboratory for one day under a strictly controlled 16-h light and 8-h dark environment and their IOP was measured every 2 h using a pneumotonometer. In the first group of 12 volunteers, habitual measurements were performed with subjects seated during the light-wake period and resting in a supine position during the dark period [38] . Nocturnal IOP was reported to be higher than diurnal IOP in the habitual position, with the difference between peak to trough IOP as high as 8.2 ± 1.4 mmHg. The increase in IOP at night was partly attributed by the authors to an increase in episcleral venous pressure and redistribution of body fluid in the supine position. In the second part of the study performed on 21 subjects, mean IOP was significantly higher in the dark period than in the light-wake period [38] and were broadly in agreement with the previous investigations. The characteristics of their diurnal IOP curve performed between 7:00 am and 5:00 pm were similar in all 3 patient groups: higher IOP in the early morning, lower in the early afternoon, and a tendency for pressure to rise again at the end of the afternoon [44] . In this study mean diurnal IOP fluctuation was 5 ± 2 mmHg. In a retrospective chart review study [42] , diurnal IOP measurements of 68 untreated glaucoma suspects and 95 patients with NTG were performed at 10:00 am, 1:00 pm, 4:00 pm, 7:00 pm, 10:00 pm, and 7:00 am. Again in the glaucoma suspects, the peak IOP was noted in the morning: at 7:00 am in the right eye and at 10:00 am in the left eye. The trough IOP was observed at 10:00 pm for both eyes. For both eyes of patients with NTG, the peak IOP occurred at 7:00 am and the trough IOP was measured at 10:00 pm. In another study [43] , diurnal IOP fluctuations between 7:00 am and 10:00 pm were found to be significantly higher in primary chronic angle-closure glaucoma (PCACG; 7.7 ± 3.0 mmHg) and POAG (8.3 ± 2.6 mmHg) groups compared to the normal controls (4.8 ± 2.5 mmHg). Afternoon peaks were more common after iridotomy in eyes with PCACG, whereas morning peaks were more frequent in the POAG eyes. In POAG, the IOP fluctuations between 8:00 am and 6:00 pm on different days were found to be broadly similar (5.0 ± 2.6 vs. 4.0 ± 1.2 mmHg; P = 0.08).
It is well established that 24-h IOP monitoring may reveal higher peaks and wider fluctuations than those recorded during office hours [9, 11, 20, 21, 45] . Nevertheless, conflicting results have been published as to the time of peak pressure, the pattern of the curve, and the extent IOP fluctuation. In some studies, the timing of peak IOP during pressure monitoring exhibited no apparent pattern [9, 20] . In a retrospective chart review of 18 patients with NTG and 11 with POAG using their prescribed topical antiglaucoma treatment, Hughes et al. [9] reported that the mean peak IOP during 24-h monitoring was 4.9 mmHg higher than the mean peak office IOP determined in the clinic during previous visits, despite the fact that the mean office IOP was similar to the mean 24-h value. [21] . In a large study [20] OHT, relative IOP reductions from baseline were documented to be: -23% at peak and -20% at trough for betaxolol 0.5%; -27% at peak and -26% at trough for timolol 0.5%; -22% at peak and -17% at trough for dorzolamide 2.0%;
-17% at peak and -17% at trough for brinzolamide 1.0%; -25% at peak and -18%
at trough for brimonidine 0.2%; -31% at peak and -28% at trough for latanoprost 0.005%; -31% at peak and -29% at trough for travoprost 0.004%; -33% at peak and -28% at trough for bimatoprost 0.03%; and finally -5%
at peak -5% at trough for the placebo [55] . In the crossover study by Orzalesi et al. [10] , 10 patients with POAG and 10 patients with OHT were treated with timolol, latanoprost, and dorzolamide for 1 month in a randomized sequence. All patients underwent four 24-h IOP curves: at baseline and after each 1-month treatment period. IOP measurements were performed at 3:00 am, 6:00 am, 9:00 am, noon, 3:00 pm, 6:00 pm, 9:00 pm and midnight using Tono-Pen with the patient supine and sitting, and a Goldmann applanation tonometer with the patient sitting at the slit lamp. In this group, the highest IOP values were measured at 9:00 am and the lowest values at midnight and 3:00 am both in the sitting and supine positions [10] . Latanoprost was more effective than dorzolamide and timolol and seemed to lead to a fairly uniform circadian reduction in IOP. Timolol was more effective than dorzolamide at 3:00 pm (P = 0.05), whereas dorzolamide performed better than timolol at midnight and 3:00 am (P = 0.05). In another 24-h study, Liu [62] . However, the IOP reduction was greater with the latanoprost and dorzolamide regimen, especially at nighttime [62] . In a similar study, dorzolamide or brinzolamide combined with latanoprost elicited a significant 24-h IOP reduction [63] . In the study by Lupinacci et al. [64] , diurnal IOP control between 8:00 am and 8:00 pm was similar in the twice daily versus three-times daily dosing of dorzolamide as adjunctive therapy to latanoprost in patients with POAG, although mean IOP reduction was significantly lower at 6:00 pm on the three-times daily regimen of dorzolamide (4.7 ± 3.3 vs. 2.3 ± 2.7 mmHg; P = 0.038). [28] showed that travoprost uniformly reduced mean 24-h IOP from 23. [77] established that bimatoprost demonstrates the greatest reduction in 24-h fluctuation 
Diurnal/24-h Fluctuation and Glaucoma Progression
The potential detrimental role of large IOP fluctuations in the development or progression of glaucoma has received increasing attention [8, 25, [78] [79] [80] [81] [82] [83] . Based on the concept that large diurnal IOP fluctuation and high peak IOP may be harmful to the glaucomatous optic nerve, many clinicians now feel that optimal glaucoma therapy should aim to minimize the circadian IOP fluctuation and to eliminate as much as possible the pressure spikes [9] .
However, it is uncertain as yet which 24-h IOP parameter (peak, mean, or fluctuation) is more important in disease progression. Barkana et al.
[84] performed a chart review of 32 patients with open-angle glaucoma whose office IOP readings did not seem to explain the severity or glaucomatous progression. All patients were medically treated or had undergone laser trabeculoplasty and/or trabeculectomy.
Pressure monitoring was carried out employing Goldmann tonometry in the sitting position from 7:00 am until midnight and Perkins tonometry in the supine position at 6:00 am. Peak IOP was detected outside of office hours in at least one eye in nearly 70% of their patients. Peak 24-h IOP was higher than that recorded in the office in 62% of cases and mean IOP fluctuation during 24-h monitoring (6.9 ± 2.9 mmHg) was significantly greater than that measured during office hours (3.8 ± 2.3 mmHg; P\0.001). The results of this 24-h IOP monitoring study led to immediate treatment change in at least one eye of almost 60% of study patients. In the study of Asrani et al. [8] , the diurnal IOP range of 5 measurements obtained in a day using home tonometry and the IOP range over 5 days were found to be significant risk factors for progression in 105 eyes of 64 patients with open-angle glaucoma. However, this study has raised some methodological issues and no study since has replicated this research approach. In another study by Bergea et al. [25] , diurnal IOP measurements and automated visual field tests were performed in 76 patients for 2 years, the majority of whom had XFG and both mean IOP and IOP variation (range and peak) were found to be significant predictors of glaucoma progression.
In the study by Wilensky et al. [78] , more than half of the patients with glaucoma investigated had one or more IOP readings above 22 mmHg with self-tonometry applied 5 times a day between awakening and bedtime for 3 to 6 days, although they had an IOP of 22 mmHg or less at 3 consecutive visits before recruitment into the study. Moreover, the peak IOP was measured either before 8:00 am or after 5:00 pm in nearly half of these cases, which means they were unlikely to have been detected in a routine office visit. More elevated IOP readings were recorded in patients with suspected or documented progression of glaucomatous damage than in patients thought to be stable or in normal subjects. In the diurnal study conducted by Thomas et al.
[ 
24-H EFFICACY OF MONOTHERAPIES
Clinical management of a patient with glaucoma is primarily based on establishing an individual target IOP that can vary depending upon parameters such as age, visual field damage, rate of progression, baseline IOP, and overall risk profile. Treatment options must be selected so that target IOP is attained considering 24-h drug efficacy. The following section presents clinical efficacy data of antiglaucoma drug classes as highlighted by key published studies.
Prostaglandin Analogs
Prostaglandins are currently the most potent topical antiglaucoma medications, achieving a mean 24-h IOP reduction of 24-29% [6, 85] .
Their efficacy appears to be fairly uniform throughout the circadian cycle [6] , although 24 -h studies generally have demonstrated that the peak efficacy of all prostaglandins occurs 8-12 h after administration [10, 12, 15, 17, 76] .
Published evidence indicates that prostaglandin efficacy is greater during the morning/daytime with evening dosing [12, 27, 77] . All prostaglandins are thought to exert their ocular hypotensive effect by increasing the uveoscleral (and to a lesser extent the trabecular) outflow of aqueous [86] . Their superior 24-h efficacy profile and their convenient dosing (once daily, mostly in the evening) have made prostaglandins a popular first-choice glaucoma therapy.
Latanoprost, the first member of this class became commercially available in 1996. It is a prostaglandin F2a isopropyl ester pro-drug, which is rapidly hydrolyzed by esterases in the cornea to the biologically active latanoprost acid [87] . Its efficacy has been extensively compared with other commonly used glaucoma medications. Orzalesi and coworkers [10] evaluated the 24-h IOP reduction achieved with latanoprost in POAG and OHT. They established that latanoprost was more efficacious in lowering IOP than the prototype beta-blocker timolol at 3:00 am, 6:00 am, 9:00 am, 12:00 am, 9:00 pm, and at midnight.
It was also more effective than the topical carbonic anhydrase inhibitor dorzolamide at 9:00 am, noon, 3:00 pm, and 6:00 pm. Quaranta et al. [85] reported similar results:
latanoprost was more efficacious than timolol from 10:00 pm to 6:00 am. No significant differences in IOP were found for the period between 8:00 am and 8:00 pm between timolol and latanoprost, while dorzolamide was as effective as latanoprost during the night from 10:00 pm to 6:00 am.
The peak efficacy of latanoprost remains a matter of debate and may differ from patient to patient, but is generally thought to occur approximately 8-12 h after administration [12, 88] . In a 6-month randomized, double-masked, multicenter study with three parallel groups (latanoprost dosed either in the morning or evening and timolol), Alm and Stjernschantz [89] showed that timolol reduced the mean diurnal IOP from 24.6 to 17.9 mmHg (27%), [6] . Specifically, travoprost has been shown to be more effective than latanoprost [96] and overall travoprost and bimatoprost appear to reduce nighttime IOP more consistently than latanoprost [68, [96] [97] [98] . Therefore, patients on travoprost or bimatoprost may be more likely to achieve a lower target 24-h pressure [6, 55, 99] . Although it remains to be established if such statistically significant 24-h IOP differences are also clinically meaningful, controlled trials employing single pressure measurements have shown that 1 mmHg of further IOP reduction can reduce the risk of glaucoma progression by approximately 10% [100, 101] . Taking these facts in account, it can be assumed that there is even more value in maintaining a lower target IOP over the full 24-h period.
Recently, Tung et al. [102] , in a sleep laboratory study, investigated the 24-h efficacy of the recently available 0.01% bimatoprost solution in a cohort of patients with either POAG (n = 3) or OHT (n = 13). In contrast to the standard 0.03% bimatoprost solution, the new formulation was developed with the aim of reducing the occurrence and severity of ocular hyperaemia while broadly maintaining the efficacy of the 0.03% solution. To achieve this, the 0.01% formulation had to contain a higher concentration of the preservative benzalkonium chloride compared to the standard 0.03% bimatoprost formulation (0.2 vs. 0.05 mg/mL).
This was deemed necessary to enhance corneal penetration and intraocular bioavailability of the new formulation. Although the authors do not report the mean 24-h efficacy of the study medication, they demonstrate a mean habitual IOP reduction of 21.7% during the day and 10.2% during the night.
There is generally limited information on the 24-h efficacy of prostaglandins in other glaucomas. Ishibashi et al. [103] investigated the effect of latanoprost on circadian sitting IOP in patients with NTG. They found that latanoprost offered a statistically significantly, but relatively small, mean 24-h IOP reduction (12.5%) in this series of patients with relatively low baseline IOP (mean IOP at baseline: 13.9 mmHg).
In a crossover,
investigator-masked 24-h study with newly diagnosed, previously untreated patients with NTG, evening-dosed latanoprost and bimatoprost exhibited similar efficacy over the 24-h period (16% reduction from baseline) and for each time-point measured [104] . A crossover study by Costagliola et al. [105] showed that the 24-h efficacy of latanoprost is superior to that of timolol 0.5% dosed twice daily in patients with NTG.
Considering the chronic, insidious nature of glaucomatous damage and the possibility that suboptimal long-term IOP control may increase the chances of disease progression [30, 83, 84] , knowledge of the long-term 24-h efficacy of all medications should be considered highly relevant. Topical therapy for glaucoma should be effective in maintaining a sustained IOP reduction over the long-term [106, 107] .
Clinical trials with latanoprost monotherapy have established a long-lasting daytime hypotensive effect with little evidence of tachyphylaxis for up to 4 years [106] [107] [108] [109] [110] . Recently, a 24-h investigation by Riva et al. [28] showed that a relatively high proportion (82%) of previously untreated patients with POAG reached and maintained a predetermined, individualized target IOP reduction between 20 and 30% with travoprost monotherapy during a 5-year follow-up period that included annual 24-h measurements. This long-term result compares well with the reported short-term 24-h efficacy of travoprost monotherapy [6] . Similarly, a multicenter study on patients with POAG treated with latanoprost monotherapy reported satisfactory IOP control in the vast majority of their patients (86%), but this was with a shorter 2-year follow-up [111] .
Timolol Maleate
To date there has been very little published 24-h evidence on other beta-blockers, except timolol maleate. Timolol is a beta-adrenergic blocker that has been used as an IOP-reducing medication since 1979. Currently, it is available both as a hydrogel formulation (0.1% or 0.5%) administered once daily and an ophthalmic solution (0.25% or 0.50%) typically administered twice daily. In a 24-h study, Konstas et al. [7] investigated the efficacy of timolol over 24 h and reported a mean circadian efficacy ranging from 10% to 25% in patients with POAG. In a subsequent 24-h study, Orzalesi et al. [10] evaluated the ocular hypotensive effect of timolol in patients with POAG and OHT and established that the nocturnal efficacy was only about half the daytime efficacy. Quaranta et al. [85] consolidated previous evidence and also documented a greater daytime IOP reduction and a smaller, yet still significant, nighttime reduction with timolol. In contrast, Liu et al.
24-H EFFICACY OF FIXED AND UNFIXED COMBINATION THERAPIES
Cumulative evidence from clinical trials clearly indicates that the majority of glaucoma patients need more than one medication to reach target IOP. The Collaborative Initial Glaucoma Treatment Study (CIGTS) found that about 75% of patients needed 2 or more medications to reach the predetermined target pressure [125] . [70, 127, 128] , only one has specifically focused on 24-h efficacy [6] and another on 24-h IOP fluctuation [77] .
Combinations of Prostaglandin Analogs with Beta-Blockers
Combination of Latanoprost and Timolol
A meta-analysis of clinical trials on the 24-h efficacy of IOP-lowering medications reported an average reduction of 33% for the LTFC [6] . A placebo-controlled crossover study was carried out in 20 patients with OHT with a follow-up of 1 month [20] . The LTFC was more efficacious than placebo in reducing 24-h IOP: the ocular hypotensive effect was in favor of LTFC both at daytime (10:00 am to 10:00 pm) and at nighttime (5.6 and 3.1 mmHg, respectively).
In a 2-month, crossover trial, Konstas et al. 19.5 ± 2.7 mmHg; P\0.001).
Combination of Bimatoprost and Timolol
Konstas et al. [76] In another crossover study, Orzalesi et al. [21] investigated the circadian IOP characteristics of 20 patients with POAG or OHT who were treated with DTFC, latanoprost, or brimonidine. This study documented greater efficacy for DTFC compared with brimonidine at 3:00 am, 9:00 am, 3:00 pm, and 6:00 pm.
Furthermore, DTFC was also more efficacious than latanoprost at 9:00 am. Eren et al. [132] conducted a double-masked, 6-week, crossover The 24-h IOP-lowering effect of DTFC was compared to that of the timolol-brimonidine fixed combination in a crossover trial [133] .
DTFC was more effective and the difference (mean -0.7 mmHg; 95% CI -1.0 to -0.3; P\0.001) reached statistical significance.
Combination of Brinzolamide and Timolol
There is limited information available on the 24-h efficacy of the brinzolamide/timolol fixed combination. Recently, the 24-h IOP reduction obtained with the brinzolamide/timolol and the brimonidine/timolol fixed combination as adjunctive therapies to travoprost was investigated in an observer-masked, crossover 24-h study in patients with POAG and XFG insufficiently controlled with travoprost [69] . administration and its 24-h efficacy remains to be determined. Although the IOP-lowering efficacy of trabeculoplasty during office hours [145] and the effect on long-term variation of IOP has been well documented previously [146] , information is currently scant on the 24-h efficacy of laser trabeculoplasty [147] . Agarwal and coworkers [148] Following ALT, a significant decrease in mean (22%), range (30%), fluctuation (25%), and peak 24-h IOP (25%) was found. Interestingly, the 16.6 ± 3.5, 22.8 ± 5.0, and 18.7 ± 3.6 mmHg, respectively. According to the results of this study, laser therapy did not meaningfully alter daytime IOP. In contrast, mean 24-h, peak, and habitual IOP were all significantly reduced. The investigators concluded that laser therapy exhibited minimal daytime, but significant nocturnal efficacy. Thus, they proposed that even when patients exhibit a poor response to laser therapy during office hours there might be a benefit from laser during the nighttime.
Conclusions
24-H IOP CONTROL WITH LASER TRABECULOPLASTY
Nonetheless, it remains unclear why this 24-h study did not detect the daytime efficacy previously reported by other investigators [1, 148, 149] . Nagar et al. [151] however, latanoprost was more efficacious (41% reduction for SLT vs. 64% for latanoprost).
Moreover, latanoprost resulted in higher success rates compared to 90°and 180°SLT treatments. The difference in efficacy between latanoprost and 360°SLT treatment did not reach statistical significance.
Kó thy and coworkers [152] were the first to report the 24-h efficacy of SLT in a group of 26 eyes of 13 patients with POAG who had been 
24-H EFFICACY OF SURGERY
